WO2009133455A3 - Pharmaceutical composition of clodipogrel - Google Patents

Pharmaceutical composition of clodipogrel Download PDF

Info

Publication number
WO2009133455A3
WO2009133455A3 PCT/IB2009/005455 IB2009005455W WO2009133455A3 WO 2009133455 A3 WO2009133455 A3 WO 2009133455A3 IB 2009005455 W IB2009005455 W IB 2009005455W WO 2009133455 A3 WO2009133455 A3 WO 2009133455A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
clodipogrel
clopidogrel
discloses
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2009/005455
Other languages
French (fr)
Other versions
WO2009133455A2 (en
Inventor
Roy Sunilendu Bhushan
Sheikh Shafiq
Shailendra Mandge
Anita Sharma
Raghupathi Kandarapu
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2009133455A2 publication Critical patent/WO2009133455A2/en
Publication of WO2009133455A3 publication Critical patent/WO2009133455A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses a pharmaceutical composition of clopidogrel or its pharmaceutically acceptable salts, particularly injectable pharmaceutical composition.
PCT/IB2009/005455 2008-05-01 2009-05-01 Pharmaceutical composition of clodipogrel WO2009133455A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN956/MUM/2008 2008-05-01
IN956MU2008 2008-05-01

Publications (2)

Publication Number Publication Date
WO2009133455A2 WO2009133455A2 (en) 2009-11-05
WO2009133455A3 true WO2009133455A3 (en) 2010-02-25

Family

ID=41255485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/005455 WO2009133455A2 (en) 2008-05-01 2009-05-01 Pharmaceutical composition of clodipogrel

Country Status (1)

Country Link
WO (1) WO2009133455A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101865A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
US20220218608A1 (en) * 2019-05-10 2022-07-14 Fordoz Pharma Corp. Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel
CN117503720B (en) * 2024-01-02 2024-03-15 济南舜景医药科技有限公司 Clopidogrel bisulfate tablet and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105102A1 (en) * 1998-08-20 2001-06-13 Sanofi-Synthelabo Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
CN1875926A (en) * 2006-07-14 2006-12-13 北京赛科药业有限责任公司 Injectable composition of clopidogrel and its salt and preparation method thereof
US20070003628A1 (en) * 2005-05-10 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
WO2008134600A1 (en) * 2007-04-27 2008-11-06 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105102A1 (en) * 1998-08-20 2001-06-13 Sanofi-Synthelabo Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
US20070003628A1 (en) * 2005-05-10 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
CN1875926A (en) * 2006-07-14 2006-12-13 北京赛科药业有限责任公司 Injectable composition of clopidogrel and its salt and preparation method thereof
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
WO2008134600A1 (en) * 2007-04-27 2008-11-06 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROWE R C ET AL: "Handbook of Pharmaceutical Excipients, EDETIC ACID", 1 January 2000, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, WASHINGTON, DC : APHA, US, PAGE(S) 191 - 194, ISBN: 9780853693819, XP002291434 *
ZHAO Q ET AL: "INJECTABLE COMPOSITION AS PLATELET AGGREGATION INHIBITORS OF***CLOPIDOGREL*** AND ITS MEDICAL SALTS AND PREPARATION THEREOF", CA, 25 January 2007 (2007-01-25), pages 1 - 2, XP002482901 *

Also Published As

Publication number Publication date
WO2009133455A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
FIC20240026I1 (en) Etrasimod or a pharmaceutically acceptable salt thereof, such as etrasimodiarginine
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
BRPI0914802A2 (en) Compound, prodrug, drug, use of the compound or a prodrug thereof.
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
PL384366A1 (en) Weld, especially for the clinker molder
AP2011005979A0 (en) Pharmaceutical composition for a hepatitis C viralprotease inhibitor.
WO2010117738A3 (en) Solid state forms of sitagliptin salts
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL206808A (en) Indolyl-pyridone derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010119455A3 (en) An injectable sustained release pharmaceutical composition
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
EP2193795A4 (en) Latanoprost-containing aqueous pharmaceutical composition
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
WO2009133455A3 (en) Pharmaceutical composition of clodipogrel
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
WO2010132390A3 (en) Method of decreasing ubiquitylated protein levels
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2325/MUMNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09738468

Country of ref document: EP

Kind code of ref document: A2